Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $53.3 million.

  • Rocket Pharmaceuticals' Total Non-Current Liabilities fell 1508.88% to $53.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.3 million, marking a year-over-year decrease of 1508.88%. This contributed to the annual value of $63.3 million for FY2024, which is 1059.71% down from last year.
  • Rocket Pharmaceuticals' Total Non-Current Liabilities amounted to $53.3 million in Q3 2025, which was down 1508.88% from $65.7 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $96.4 million for Q1 2021, and its period low was $42.2 million during Q4 2021.
  • For the 5-year period, Rocket Pharmaceuticals' Total Non-Current Liabilities averaged around $56.9 million, with its median value being $56.0 million (2024).
  • Over the last 5 years, Rocket Pharmaceuticals' Total Non-Current Liabilities had its largest YoY gain of 4100.34% in 2022, and its largest YoY loss of 5593.23% in 2022.
  • Rocket Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $42.2 million in 2021, then surged by 41.0% to $59.5 million in 2022, then increased by 18.99% to $70.8 million in 2023, then decreased by 10.6% to $63.3 million in 2024, then decreased by 15.83% to $53.3 million in 2025.
  • Its Total Non-Current Liabilities was $53.3 million in Q3 2025, compared to $65.7 million in Q2 2025 and $57.8 million in Q1 2025.